Clinical Trials Sponsored by Priyanka Sharma

Total 12527 results

Priyanka Sharma

Completed

Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer (NeoSTOP)

Triple-negative Breast Cancer

United States
Priyanka Sharma
Novartis Pharmaceuticals

Completed

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Breast Cancer

United States
Priyanka Sharma
Bristol-Myers Squibb; Celgene Corporation

Active, not recruiting

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Breast Cancer | Triple-Negative Breast Cancer

United States
Pryanka Relan

Active, not recruiting

Oxygen Requirements and Use in Patients With COVID-19 in LMICs (O2CoV2)

Covid19 | COVID-19 Pneumonia

Switzerland
Dr.K.Sai Priyanka
Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre

Completed

Comparison of Serum Trefoil Factor 3 in Patients With Gingivitis and Periodontitis After Scaling and Root Planing (CSTF3PGPSR)

Gingivitis and Periodontal Diseases
Ain Shams University
Eva Pharma

Not yet recruiting

Alpha Lipoic Acid in Pediatrics on Hemodialysis

Hemodialysis Complication | Pediatric Kidney Disease | Cardiovascular Complication

Egypt
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
Astellas Pharma Europe B.V.
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) (SUNSHINE)

Clostridium Difficile-associated Diarrhea (CDAD)

United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
Astellas Pharma Europe Ltd.
Merck Sharp & Dohme LLC

Completed

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND)

Clostridium Difficile

Greece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
TME Pharma AG
Merck Sharp & Dohme LLC

Not yet recruiting

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (OPTIMUS)

Metastatic Pancreatic Cancer
Redx Pharma Plc
Merck Sharp & Dohme LLC

Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)

Advanced Solid Tumours

United Kingdom, Australia
Acerta Pharma BV
Merck Sharp & Dohme LLC

Active, not recruiting

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)

Multiple Myeloma | Hodgkin Lymphoma | Waldenström Macroglobulinemia | Burkitt Lymphoma | Small Lymphocytic Lymphoma (SLL) | Hairy Cell Leukemia | CLL | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Richter's Syndrome | Indolent Non Hodgkin Lymphoma | Marginal Zone Lymphomas | Mediastinal Large B Cell...

United States
4D pharma plc
Merck Sharp & Dohme LLC

Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Oncology

United States
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
TME Pharma AG
Merck Sharp & Dohme LLC

Completed

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (Keynote-559)

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer

Germany
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer (KEYNOTE166)

Carcinoma, Non-Small-Cell Lung

United States
Merck Sharp & Dohme LLC
MDS Pharma Services

Completed

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Breast Neoplasm
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
invoX Pharma Limited
Merck Sharp & Dohme LLC

Recruiting

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Metastatic Cancer | Advanced Cancer

Spain, United States
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer (KEYNOTE144)

Metastatic Pancreatic Cancer

United States
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

Ovarian Cancer

United States
Merck Sharp & Dohme LLC
Essex Pharma GmbH

Completed

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

Breast Cancer
Merck Sharp & Dohme LLC
AESCA Pharma GmbH

Terminated

Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)

Carcinoma, Non-Small-Cell Lung
PT Sydna Farma
PT Pharma Metric Labs

Completed

Bioequivalence Study of Cyproterone Acetate and Ethinyl Estradiol in Healthy Female Volunteers

Drug Use

Indonesia
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE147)

Squamous Cell Carcinoma of the Head and Neck

United States
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer (KEYNOTE143)

Metastatic Urothelial Carcinoma

United States
Merck Sharp & Dohme LLC
AESCA Pharma GmbH

Terminated

Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)

Rheumatoid Arthritis
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of ASP1570 Taken by Itself or With Pembrolizumab in Adults With Solid Tumors

Advanced Solid Tumors

United States, Japan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors

Metastatic Cancer | Advanced Cancer | Solid Tumors

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Canada, Taiwan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Portugal, Spain, United Kingdom, Italy, Canada, Japan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Canada, Italy, Japan, Portugal, Spain, United Kingdom
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

Japan
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
PT. Pyridam Farma Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of Metformin Hydrochloride 500 mg Film-Coated Tablets in Indonesia Healthy Subject

Drug Use

Indonesia
Laboratories Leon Farma, S.A.
Chemo France

Completed

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Contraception

United States
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic

Canada, United States, Israel, Puerto Rico, Taiwan, Korea, Republic of, Australia, Chile, China, France, Norway
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

China
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Not yet recruiting

Substudy 01A: Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Prostatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States, Puerto Rico, Israel, Australia, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain
PT Kalbe Farma Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of 20 mg Omeprazole Capsules in Indonesia Healthy Subject

Drug Use

Indonesia
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)

Urothelial Cancer

United States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand and more
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Active, not recruiting

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Italy, Spain, Canada, France, Puerto Rico
PT. Kimia Farma (Persero) Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of Furosemide 40 mg Tablet in 24 Indonesian Healthy Volunteers

Drug Use

Indonesia
Salma Hesham Elhoufi

Recruiting

Effectiveness of Topical Olive Oil in Prevention and Management of Radiation Induced Oral Mucositis

Oral Mucositis (Ulcerative) Due to Radiation | Radiation-Induced Mucositis | Radiation Mucositis

Egypt
PT. Kimia Farma (Persero) Tbk
PT Pharma Metric Labs

Completed

Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject

Drug Use

Indonesia
NETRIS Pharma
Centre Leon Berard; Merck Sharp & Dohme LLC

Recruiting

GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET)

Endometrial Carcinoma | Cervix Carcinoma

France
Merck Sharp & Dohme LLC
Astellas Pharma Inc; Seagen Inc.

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

Bladder Cancer

Hungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more

Clinical Trials Sponsored by Priyanka Sharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations